Related Experiment Videos
(Re-)Engineering tumor cell-selective replicating adenoviruses: a step in the right direction toward systemic therapy
1Cancer Research, Cerus Corporation, 2411 Stanwell Dr., Concord, CA 94520, USA. tom_dubensky@ceruscorp.com
Cancer Cell
|June 28, 2002
Abstract:
An approach combining redundant controls to restrict the productive infection of adenoviruses to cells that are disrupted in the pRb pathway-a hallmark of human cancer-has resulted in a novel oncolytic virus that may be well suited for systemic administration to treat metastatic disease.
Insights
Researchers developed a novel oncolytic virus targeting cancer cells with a disrupted pRb pathway. This engineered adenovirus shows promise for treating metastatic disease through systemic administration.
Area of Science:
- Oncolytic virotherapy
- Cancer biology
- Gene therapy
Background:
- The retinoblastoma (pRb) pathway is frequently disrupted in human cancers.
- Adenoviruses are common viruses that can be engineered for therapeutic purposes.
- Targeting cancer-specific pathways is crucial for effective oncolytic virus therapy.
Purpose of the Study:
- To develop a novel oncolytic virus with enhanced cancer cell specificity.
- To engineer adenoviruses that selectively infect and replicate in pRb-deficient cancer cells.
- To assess the potential of this oncolytic virus for systemic treatment of metastatic disease.
Main Methods:
- Utilizing redundant genetic controls to restrict viral replication.
- Engineering adenoviruses to target cells with defects in the pRb pathway.
- Evaluating viral infectivity and replication in cancer cell models.
Main Results:
- A novel oncolytic adenovirus was successfully generated.
- The engineered virus demonstrated restricted productive infection to cells with disrupted pRb pathways.
- The virus exhibits potential for systemic administration in treating metastatic cancers.
Conclusions:
- The developed oncolytic virus offers a targeted approach for cancer therapy.
- Restricting viral infection to pRb-disrupted cells enhances safety and efficacy.
- This novel oncolytic adenovirus is a promising candidate for systemic treatment of metastatic disease.